Urinary Excretions of Albumin and Type IV Collagen in Normotensive and Hypertensive Subjects.

Ishimitsu, Toshihiko; Murayama, Naoki; Meguro, T; Kageyama, Yoichi; Okada, Kazuhisa; Okubo, Yasuhiro; Takeda, Shigeyuki; Hasegawa, Kazuo; Kikegawa, Yoshinobu; Ohwada, Tsuneo; Hosoya, Hideo; Minami, Junichi; Ono, Hitoshi; Matsuoka, Hiroaki

doi:10.1291/hypres.23.459

Cited by 13 publications

(13 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…1): u-IVc had positive correlation with age, blood pressure, u-Prot, u-β 2 MG, NAG, HbA 1 c and SI, while u-IVc had negative correlation with eGFR and serum albumin. These findings were identical to the past knowledge [17,22], which confirmed that the results were true. Moreover, our large-size study enabled multiple regression analysis to find independent factors for u-IVc.…”

Section: Discussionsupporting

confidence: 91%

Urinary Type IV Collagen in Nondiabetic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

Background: Type IV collagen is one of the major components of basement membrane. In diabetic nephropathy, it is already known that urinary excretion of type IV collagen increases with the disease progression. However, in nondiabetic kidney disease, urinary type IV collagen (u-IVc) levels have not been extensively investigated. The aim of this study was to evaluate u-IVc levels in various nephropathies except diabetic nephropathy. Methods: u-IVc levels were measured cross-sectionally from 527 biopsy-proven nondiabetic renal disease patients at tertiary care hospitals by one-step sandwich enzyme immunoassay. Results: On simple regression analyses, u-IVc levels had positive correlation with age, blood pressure, urinary protein (u-Prot), urinary β₂ microglobulin, urinary N-acetyl-β-D-glucosaminidase, HbA₁c, and selectivity index (SI), while u-IVc had negative correlation with eGFR and serum albumin. Multiple regression analyses revealed that u-IVc was positively correlated with u-Prot, HbA₁c and SI. Among biopsy-proven nondiabetic nephropathies, elevation of u-IVc was distinctively observed in membranous nephropathy and anti-neutrophil cytoplasmic antibody (ANCA)-associated glomerulonephritis. Conclusion: u-IVc levels were elevated with the increase in u-Prot, HbA₁c and SI. In addition, among nondiabetic kidney disease, elevation of u-IVc was observed in patients with membranous nephropathy and ANCA, which might reflect the thickening of basement membrane or severe kidney damage.

show abstract

Section: Discussionsupporting

confidence: 91%

Urinary Type IV Collagen in Nondiabetic Kidney Disease

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Furthermore, in recent years it has been reported that the urinary concentrations of type IV collagen increase in diabetic nephropathy patients and in db/db mice (13,14). Because type IV collagen in the urine is considered to be derived from mesangial matrix, glomerular basement membrane, and tubulointerstitial tissue, it is likely that urinary excretion of type IV collagen reflects fibrotic changes in diabetic kidneys (23,25). Therefore, the observed SMP-534-induced inhibition of the increase in urinary type IV collagen excretion may also reflect an inhibitory effect of this compound on deterioration of renal fibrosis.…”

Section: Discussionmentioning

confidence: 99%

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabeticdb/dbmice

Sugaru¹,

Nakagawa²,

Ono-Kishino³

et al. 2006

American Journal of Physiology-Renal Physiology

View full text Add to dashboard Cite

benzamide (SMP-534) reduces extracellular matrix (ECM) production induced by transforming growth factor-␤ (TGF-␤) in vitro and prevents the accumulation of ECM in glomeruli in rat Thy-1 nephritis models. In this study, we examined the longterm effects of SMP-534 on renal insufficiency and glomerulosclerosis in db/db mice, which are models of type 2 diabetes. A diet containing SMP-534 was given to the mice from the age of 9 to 25 wk, and blood and urine analysis were performed at 8, 17, and 25 wk. At the end of study, kidney tissues were analyzed histologically. Treatment with SMP-534 dose dependently suppressed the increase of urinary albumin and type IV collagen excretion in db/db mice. The renal histological analysis showed that SMP-534 dose dependently suppressed the increase of mesangial expansion in the kidney. In the immunohistological analysis, fibronectin and type IV collagen expression were lower in SMP-534-treated db/db mice compared with vehicle-treated db/db mice. This study suggested that SMP-534 ameliorated the increase of ECM production in kidney of db/db mice, possibly through the inhibition of TGF-␤ action. Hence, antifibrotic agents such as SMP-534 might be a new therapeutic option for the treatment of diabetic nephropathy. urinary type IV collagen; diabetic nephropathy; antifibrotic agent; extracellular matrix; transforming growth factor-␤

show abstract

“…Several studies have suggested that the overproduction of extracellular matrix proteins underlying glomerulosclerosis in diabetes is associated with the increased excretion of type IV collagen in the urine (14,19). In some cases an increase of urinary type IV collagen excretion precedes an increase of urinary albumin excretion (20).…”

Section: Discussionmentioning

confidence: 99%

Low-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure.

et al. 2003

View full text Add to dashboard Cite

To determine the effect of a low-dose angiotensin receptor blocker, candesartan, on early kidney damage associated with diabetes. Fifty-two patients with type 2 diabetes with normo-and microalbuminuria participated in this study. Nineteen patients with high-normal and mildly high blood pressure received low-dose candesartan cilexetil at 4 mg daily (candesartan group), and 33 patients did not receive candesartan (control group). Blood pressure, urinary excretion of albumin, transferrin, and type IV collagen (expressed as urinary creatinine index) and plasma parameters were determined at baseline and at 2, 6, 12 and 18 months after the start of candesartan therapy. Baseline urinary albumin, transferrin, and type IV collagen excretions was similar in the control and candesartan groups. The higher baseline systolic blood pressure was decreased by candesartan treatment to a level similar to that in the control group, such that blood pressure was comparable between the control and candesartan groups during the run-in period. In the control group, urinary albumin excretion was significantly increased at 18 months when compared with baseline, while urinary albumin excretion did not increase in the candesartan group throughout the study. Urinary transferrin excretion was significantly increased at 6, 12, and 18 months when compared with baseline in the control group, while it did not increase in the candesartan group during the study. In both groups, urinary type IV collagen excretion did not change significantly during the study. Hemoglobin A1c, serum urea nitrogen, creatinine, albumin, and lipids were comparable between the two groups throughout the study.

show abstract

Urinary Excretions of Albumin and Type IV Collagen in Normotensive and Hypertensive Subjects.

Cited by 13 publications

References 35 publications

Urinary Type IV Collagen in Nondiabetic Kidney Disease

Urinary Type IV Collagen in Nondiabetic Kidney Disease

SMP-534 ameliorates progression of glomerular fibrosis and urinary albumin in diabeticdb/dbmice

Low-Dose Candesartan Cilexetil Prevents Early Kidney Damage in Type 2 Diabetic Patients with Mildly Elevated Blood Pressure.

Contact Info

Product

Resources

About